合并症对接受免疫治疗的晚期头颈癌患者结局的影响
研究纳入93例接受免疫治疗的晚期头颈癌患者,按合并症指数(CCI < 1 为无合并症组,CCI ≥ 1 为有合并症组)分组比较临床结局。无合并症组总生存期(aHR = 2.74,95% CI [1.18, 6.40],p = 0.02)和无进展生存期(aHR = 2.07,95% CI [1.03, 4.16],p = 0.04)更长,肿瘤缓解率更高(CCI < 1 组 32% vs CCI ≥ 1 组 14%,p = 0.05),但免疫相关不良事件风险更高(p = 0.05)。作者认为合并症应作为晚期头颈癌免疫治疗临床决策中的重要预后因素。
要点
- 无合并症组(CCI < 1)总生存期优于有合并症组(CCI ≥ 1),aHR = 2.74(95% CI [1.18, 6.40],p = 0.02)。
- 无合并症组无进展生存期优于有合并症组,aHR = 2.07(95% CI [1.03, 4.16],p = 0.04)。
- 肿瘤缓解率 CCI < 1 组 32% vs CCI ≥ 1 组 14%(p = 0.05),免疫相关不良事件风险无合并症组更高(p = 0.05)。
核心结论
- 作者认为合并症应作为晚期头颈癌患者接受免疫治疗时临床决策的重要预后因素。
研究设计与样本
- 研究纳入93例接受免疫治疗的晚期头颈癌患者,按合并症指数(CCI < 1 为无合并症组,CCI ≥ 1 为有合并症组)分组比较临床结局。
主要发现
- 无合并症组总生存期长于有合并症组,aHR = 2.74(95% CI [1.18, 6.40],p = 0.02)。
- 无合并症组无进展生存期长于有合并症组,aHR = 2.07(95% CI [1.03, 4.16],p = 0.04)。
- 肿瘤缓解率 CCI < 1 组 32% vs CCI ≥ 1 组 14%(p = 0.05)。
- 免疫相关不良事件风险无合并症组更高(p = 0.05)。
临床怎么用
- 作者认为合并症应作为晚期头颈癌患者接受免疫治疗时临床决策的重要预后因素。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To explore the impact of pre-existing comorbidities on immunotherapy response, overall and progression-free survival, and immune-related adverse events (irAEs) of patients with advanced head and neck cancer (HNC) treated with immunotherapy. PATIENTS AND METHODS: Ninety-three patients treated with immunotherapy were identified and stratified into comorbidity absent or present (CCI < 1 and CCI ≥ 1, respectively) cohorts, and clinical outcomes were compared between these two groups. RESULTS: Patients with no comorbidities had longer overall survival (aHR = 2.74, 95% CI [1.18, 6.40], p = 0.02) and progression-free survival (aHR = 2.07, 95% CI [1.03, 4.16], p = 0.04) and a higher tumor response rate (32% in CCI < 1 vs. 14% in CC ≥ 1, p = 0.05). Risk for irAEs was higher in the comorbidity absent group (p = 0.05). CONCLUSION: Comorbidity should be considered as a significant prognostic factor in clinical decision-making for patients with advanced HNC undergoing immunotherapy.
引用
- Guller M, Cooper DJ, Alkhatib H, et al. Impact of comorbidities on outcomes in patients with advanced head and neck cancer undergoing immunotherapy. Head Neck. 2023. PMID: 37682116. doi:10.1002/hed.27502
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。